NEU 0.15% $13.13 neuren pharmaceuticals limited

Share Price, page-3172

  1. 2,852 Posts.
    lightbulb Created with Sketch. 600
    The main question for me (where investment risk is involved) is what reasons might there be for trofinetide not receiving approval?

    I, frankly, cannot see one.

    Surely if there was an administrative concern (eg packaging) that would have been addressed within the 6 month period.

    Given some of the dubious approvals that have been given in recent years that hottod has highlighted, I'm calling a slam dunk.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.